Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Status:
Suspended
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Patients are invited to participate in a research study of liver perfusion (how blood flows
to the liver over time). Researchers hope to learn whether perfusion characteristics of liver
metastases may be predictive of response to treatment and whether liver perfusion
characteristics can be used to follow response to treatment. Patients were selected as a
possible participant in this study because they are identified as having liver metastases
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Collaborators:
National Cancer Institute (NCI) Philips Healthcare